European Innovation Council

Stablepharma Ltd is a biotechnology company based in Bath, United Kingdom, focused on developing innovative processes for vaccine stabilization. Its technology platform, StablevaX™, transforms existing approved vaccines, therapeutics, and diagnostics into thermostable products that do not require refrigeration, addressing significant challenges in cold chain logistics. By enabling pre-dosed and stable vaccine delivery, Stablepharma aims to eliminate waste and reduce costs in the distribution of medical products. The company has identified up to 60 vaccine candidates suitable for its technology and collaborates actively with global vaccine manufacturers, academic institutions, and non-governmental organizations to advance its pipeline of thermostable solutions. Established in 2012, Stablepharma is dedicated to improving access to vaccines for children and adults, while also contributing to reduced carbon dioxide emissions in the healthcare sector.

AlzeCure Pharma AB is a pharmaceutical company based in Huddinge, Sweden, that specializes in developing drug therapies aimed at treating diseases affecting the central nervous system, with a particular emphasis on Alzheimer's disease. Established in 2012, the company is advancing multiple drug candidates through its research platforms, NeuroRestore and Alzstatin, among others. Current projects include ACD855, which is undergoing Phase I clinical trials for sleep disruptions, traumatic brain injuries, and Alzheimer's disease, along with several other candidates targeting Alzheimer's: ACD856, ACD679, and ACD680. Additionally, AlzeCure is developing ACD857 for eye and ear conditions, and VR1 for neuropathic pain, alongside TrkA-NAM for osteoarthritic pain. Through its focused research initiatives, AlzeCure Pharma aims to address significant unmet medical needs in neurodegenerative diseases.

Elicera Therapeutics is a clinical-stage immuno-oncology company based in Sweden that focuses on developing innovative cell and gene therapies to treat cancer. The company’s portfolio includes four drug candidates: two oncolytic virus therapies, ELC-100 and ELC-201, and two CAR T-cell treatments, ELC-301 and ELC-401. Additionally, Elicera has developed a universal CAR T-cell technology platform named iTANK (ELC-001), designed to enhance the efficacy of CAR T-cell therapies by enabling a multi-targeted approach against solid tumors. With its commitment to advancing immune-based cancer treatments, Elicera Therapeutics aims to improve outcomes for patients facing various forms of cancer.

Acorai is a medical device company focused on developing a non-invasive heart failure monitoring platform that centers around direct intracardiac pressure monitoring (ICPM). The company utilizes a unique combination of sensor technologies and machine learning to enable accurate and cost-effective heart failure management. Acorai's technology allows for the non-invasive monitoring of cardiac and pulmonary pressure through the analysis of acoustic, vibratory, and waveform data, making it the only proven method to enhance outcomes for heart failure patients. The device has received clinical validation and has been designated as an FDA Breakthrough Device, with plans to enter the market in 2025. By enabling healthcare professionals to proactively adjust medications, Acorai aims to reduce both the rates of heart failure re-hospitalization and mortality.

Innoventric is a medical device company based in Ness-Ziona, Israel, focused on developing innovative percutaneous solutions for Tricuspid Regurgitation and right heart disease. Founded in 2017, the company has made significant advancements with its proprietary Trillium™ technology, designed to treat Tricuspid Valve Regurgitation. Innoventric's device features a functional tricuspid valve replacement that employs cross-caval anchoring and a multi-valve design, aimed at enhancing blood flow regulation. The company has conducted over ten implantations of the Trillium™ technology as part of its first human clinical trial in Europe. Additionally, Innoventric maintains a comprehensive patent portfolio for the Trillium™ and related technologies, positioning itself as a key player in the structural heart medical device sector.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, founded in 2019. It specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. The company has created the world's first graphene-based brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation. This innovative technology allows for real-time monitoring and adaptive, personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. By utilizing AI-driven solutions, INBRAIN maximizes therapeutic outcomes while minimizing side effects. The company is also expanding its capabilities through strategic partnerships, including collaborations with Merck KGaA and its subsidiary INNERVIA Bioelectronics, to explore applications in peripheral nerve and systemic diseases, advancing the field of neurotechnology and bioelectronics.

Oryl Photonics specializes in developing laboratory instruments for pharmaceutical and biotech companies. Their core product provides a simple, reliable, and cost-effective method for measuring solubility, contributing to accelerated drug development and improved medicine. The company's unique technology preserves valuable substances during testing, offering a solubility measurement service that empowers researchers to make data-driven decisions and expedite product development.

UroMems is a medical device company dedicated to addressing specific clinical needs related to urinary conditions that significantly impact patients' quality of life. The company specializes in the design, development, and commercialization of active implantable medical devices. Its innovative approach aims to enhance existing surgical treatments by minimizing associated side effects and ensuring that patients receive appropriate care promptly. Through its commitment to improving treatment options, UroMems seeks to benefit a wide range of patients facing urinary health challenges.

King's College London is a public research university in London, United Kingdom, and a constituent college of the University of London. Founded in 1829 by King George IV and the Duke of Wellington, it operates from multiple central London campuses and a campus in Denmark Hill, with a strong emphasis on medical and biomedical research and education. The institution supports a large community of students and staff and is known for its extensive graduate and postgraduate programmes. It is a founding member of the King's Health Partners academic health sciences centre and participates in major research and academic networks, including the Russell Group and Universities UK.

RS Research is a clinical-stage biotechnology company based in Istanbul, Turkey, focused on developing innovative nanomedicines for cancer treatment. Founded in 2015, the company has established a proprietary drug delivery platform known as Sagitta®, which enhances the therapeutic index of its drug candidates. RS Research’s pipeline includes multiple proprietary programs at various stages of preclinical and clinical development, with its lead candidate, RS-0139, currently undergoing Phase I clinical trials in oncology patients. The company also offers a range of services, including preclinical absorption and metabolism assessments, bioanalytical testing, and patent consulting. Additionally, RS Research operates a GMP-certified production facility for the manufacture of clinical batch drug candidates and actively engages in co-development projects with international partners.

NETRIS Pharma S.A.S. is a biotechnology company based in Lyon, France, focused on the identification and development of therapeutic molecules aimed at treating various forms of cancer. Established in 2008, the company specializes in targeting dependence receptors, which are trans-membrane proteins that play a crucial role in cellular signaling and tumor control. NETRIS Pharma conducts both in vitro and in vivo research, as well as preclinical practices, to manufacture drugs specifically for the treatment of breast cancer, lung cancer, glioblastoma, and neuroblastoma. Through its innovative approach, the company aims to advance cancer therapies and contribute to improved patient outcomes in the pharmaceutical industry.

Antabio is a private biopharmaceutical company based in Labege, France, focused on developing innovative treatments for drug-resistant infections, particularly targeting critical priority pathogens. Founded in 2009, the company specializes in creating novel antibacterial resistance-breakers, including stand-alone inhibitors of bacterial metalloenzymes. These inhibitors are designed to be combined with existing antibiotics, such as carbapenems, to restore their efficacy against the most challenging pathogens responsible for life-threatening infections, including carbapenem-resistant nosocomial pneumonia. Antabio aims to address significant unmet medical needs in the treatment of drug-resistant infections, ultimately providing healthcare professionals with effective medicinal products to combat these critical health challenges. The company has been recognized for its work, receiving a Wellcome Trust Seeding Drug Discovery Award.

NEOGAP Therapeutics is a clinical-stage biopharmaceutical startup focused on immuno oncology. Their pharmaceutical product, personalized tumor trained lymphocytes, offers even one customized cell treatment that is meant to precisely target and destroy cancer in a tailored environment, with very minor side effects.

Acorai is a medical device company focused on developing a non-invasive heart failure monitoring platform that centers around direct intracardiac pressure monitoring (ICPM). The company utilizes a unique combination of sensor technologies and machine learning to enable accurate and cost-effective heart failure management. Acorai's technology allows for the non-invasive monitoring of cardiac and pulmonary pressure through the analysis of acoustic, vibratory, and waveform data, making it the only proven method to enhance outcomes for heart failure patients. The device has received clinical validation and has been designated as an FDA Breakthrough Device, with plans to enter the market in 2025. By enabling healthcare professionals to proactively adjust medications, Acorai aims to reduce both the rates of heart failure re-hospitalization and mortality.

Epigene Labs SAS is a biotechnology firm focused on enhancing precision oncology through its advanced technology platform that utilizes artificial intelligence. Founded in 2019 and headquartered in Paris, France, with an additional office in Boston, Massachusetts, the company addresses the significant challenges of aggregating, analyzing, and visualizing extensive genomic data in cancer research. By integrating proprietary data from partners with publicly available datasets, Epigene Labs provides medical researchers with actionable insights and user-friendly analytics. The company collaborates with leading cancer centers and prominent biotech firms to develop intelligence-augmenting services that support drug discovery and research in precision oncology. Its innovative approach aims to transform genomic data into effective strategies for targeted cancer therapies.

Innitius specializes in developing diagnostic devices aimed at enhancing women's health, particularly in the context of preterm birth. Utilizing innovative torsional ultrasound technology, the company has created a patented intravaginal probe that transmits torsional waves to assess changes in tissue consistency. This technology enables medical practitioners to evaluate the risk of preterm birth and the likelihood of successful labor induction. By providing actionable diagnostics, Innitius helps healthcare providers accurately identify false indications of premature labor, thereby improving patient care and outcomes in obstetrics.

RUBYnanomed provides non-invasive monitoring of cancer progression. They enable the analysis of their phenotypic, genetic, and functional characteristics, facilitating unprecedentedly frequent monitoring of cancer progression in a minimally invasive, cost-efficient way. They enable oncologists to detect and analyze the evolution of cancer subtypes and therapeutic resistance mechanisms in each patient, providing personalized therapy insights to treat their patients.

Xeltis AG, established in 2006, is a clinical-stage medical device company based in Zurich, Switzerland, with additional operations in the Netherlands and the USA. The company specializes in developing bio-absorbable heart valves and blood vessels using a proprietary polymer-based technology. Xeltis' RestoreX platform enables the body's natural healing system to develop tissue that replaces the implant, forming a new functional valve or vessel. The company's restorative devices include implantable small diameter blood vessels for hemodialysis and coronary artery bypass graft (CABG) surgery, as well as pulmonary heart valves, with ongoing clinical trials. Xeltis has raised funding from various venture capital firms and European institutions, including a €30 million round in 2021.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, founded in 2019. It specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. The company has created the world's first graphene-based brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation. This innovative technology allows for real-time monitoring and adaptive, personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. By utilizing AI-driven solutions, INBRAIN maximizes therapeutic outcomes while minimizing side effects. The company is also expanding its capabilities through strategic partnerships, including collaborations with Merck KGaA and its subsidiary INNERVIA Bioelectronics, to explore applications in peripheral nerve and systemic diseases, advancing the field of neurotechnology and bioelectronics.

ADmit Therapeutics, S.L. is a biotechnology company based in Begues, Spain, focused on developing diagnostic tests for the early detection of Alzheimer’s disease. Founded in 2017, the company utilizes epigenetic analysis of blood samples to identify a series of mitochondrial biomarkers, which are unrelated to traditional markers such as ß-amyloid or tau. By employing next-generation sequencing to analyze methylcytosines in mitochondrial DNA, ADmit Therapeutics provides medical practitioners with a simplified method for detecting early-stage Alzheimer’s disease. This innovative approach not only aids in diagnosis but also supports pharmaceutical companies in the accelerated identification of potential curative drugs.

Carthera is a clinical-stage medtech company focused on developing innovative ultrasound-based medical devices for treating brain disorders. Its proprietary device, SonoCloud®, is an intracranial ultrasound implant that, when used in conjunction with an intravenous microbubble agent, temporarily opens the blood-brain barrier. This mechanism significantly enhances the delivery of therapeutic molecules to the brain, potentially providing new treatment options for debilitating neurological conditions. Through its technology, Carthera aims to enable healthcare professionals to address challenging brain disorders more effectively.

InProTher Aps is a biotechnology company based in Copenhagen, Denmark, focusing on the development of innovative vaccine technologies and candidates within the field of immunotherapy. Established in 2011, the company is dedicated to creating the first adaptive immune therapy that targets immunosuppressive genes associated with ancient retroviruses. InProTher is also engaged in the development of products aimed at combating HIV, papilloma viruses, and various forms of cancer. Through its research and development efforts, InProTher seeks to advance treatment options in the evolving landscape of immunotherapy.

Arthex Biotech S.L. is a biotechnology company founded in 2019 and based in Paterna, Spain. It specializes in the development of antisense RNA treatments specifically aimed at addressing genetic diseases and disorders where microRNAs play a significant role. As a spin-off from the University of Valencia, Arthex Biotech leverages a strong foundation in drug discovery and has a team comprising experts with extensive experience in neuromuscular diseases. The company focuses on creating innovative therapies for conditions with unmet medical needs, providing new treatment options for patients suffering from rare genetic diseases and other high-need medical issues. With guidance from esteemed scientific and clinical advisors, Arthex Biotech is committed to advancing its product development to improve patient outcomes.

Smart Immune is a clinical-stage biotechnology company dedicated to advancing hematopoietic stem cell-based biotherapies aimed at improving the prognosis and quality of life for patients with severe diseases. The company's primary focus is on its innovative cell therapy program that utilizes T cell progenitors, known as ProTcells, which are designed to facilitate a rapid and safe immune recovery following transplantation. This program is complemented by integrative developments in targeted conditioning, gene therapy, and genome editing, allowing for the creation of next-generation treatments. Smart Immune's approach aims to provide effective allogeneic T-cell therapies for patients suffering from life-threatening conditions, particularly hematological malignancies and primary immune deficiencies.

Smart Immune is a clinical-stage biotechnology company dedicated to advancing hematopoietic stem cell-based biotherapies aimed at improving the prognosis and quality of life for patients with severe diseases. The company's primary focus is on its innovative cell therapy program that utilizes T cell progenitors, known as ProTcells, which are designed to facilitate a rapid and safe immune recovery following transplantation. This program is complemented by integrative developments in targeted conditioning, gene therapy, and genome editing, allowing for the creation of next-generation treatments. Smart Immune's approach aims to provide effective allogeneic T-cell therapies for patients suffering from life-threatening conditions, particularly hematological malignancies and primary immune deficiencies.

TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses to enhance T-cell therapies for cancer treatment. Established in 2013, the company focuses on utilizing its patented technology to improve tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibiting antibody treatments. TILT Biotherapeutics is advancing products such as TILT-123, TILT-234, and TILT-321, which aim to modify the tumor microenvironment and boost immune responses against cancer. The company's innovative approach holds promise for achieving effective results in treating solid tumors, paralleling the successes seen in hematological tumors.

TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses to enhance T-cell therapies for cancer treatment. Established in 2013, the company focuses on utilizing its patented technology to improve tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibiting antibody treatments. TILT Biotherapeutics is advancing products such as TILT-123, TILT-234, and TILT-321, which aim to modify the tumor microenvironment and boost immune responses against cancer. The company's innovative approach holds promise for achieving effective results in treating solid tumors, paralleling the successes seen in hematological tumors.

iLoF, or Intelligent Lab on Fiber, is a technology company specializing in the integration of photonics and artificial intelligence to enhance drug discovery and development. The company has developed a patented system that identifies and captures unique features of gold-standard biomarkers, creating a cloud-based digital library of these biological profiles. This platform allows for the collection of extensive data, which facilitates personalized medicine by enabling healthcare companies to conduct more efficient and patient-centric clinical trials. By employing a multidisciplinary approach that involves physicists, biologists, and data scientists, iLoF aims to accelerate the development of tailored treatments, ultimately improving patient outcomes and reducing the costs associated with drug development.

Arctic Therapeutics is a drug discovery and development company that focuses on identifying the genetic underpinnings of both rare and common diseases. Utilizing bioinformatic approaches and artificial intelligence, the company aims to mitigate the risks associated with traditional drug development while significantly reducing the costs and time required to bring effective treatments to patients. With over 20 years of expertise in international genomics research, Arctic Therapeutics employs an innovative methodology in its drug development efforts. Collaborating closely with the Center for Applied Genomics at the Children's Hospital of Philadelphia, the company is actively involved in repurposing and developing breakthrough medical treatments. Notably, Arctic Therapeutics is working on a drug candidate for Alzheimer’s disease that has the potential to become the first cure for dementia, addressing both treatment and prevention. The company was inspired by Dr. Hakon Hakonarson, a prominent figure in applied genomics, whose work has been recognized as pioneering in the field of genetic research and therapeutic development.

Arctic Therapeutics is a drug discovery and development company that focuses on identifying the genetic underpinnings of both rare and common diseases. Utilizing bioinformatic approaches and artificial intelligence, the company aims to mitigate the risks associated with traditional drug development while significantly reducing the costs and time required to bring effective treatments to patients. With over 20 years of expertise in international genomics research, Arctic Therapeutics employs an innovative methodology in its drug development efforts. Collaborating closely with the Center for Applied Genomics at the Children's Hospital of Philadelphia, the company is actively involved in repurposing and developing breakthrough medical treatments. Notably, Arctic Therapeutics is working on a drug candidate for Alzheimer’s disease that has the potential to become the first cure for dementia, addressing both treatment and prevention. The company was inspired by Dr. Hakon Hakonarson, a prominent figure in applied genomics, whose work has been recognized as pioneering in the field of genetic research and therapeutic development.

iThera Medical is a biotechnology company founded in 2010 as a spin-off from the Helmholtz Zentrum Muenchen, specializing in photonic molecular imaging technology. The company focuses on the development of its proprietary multispectral optoacoustic tomography (MSOT) technology, which offers real-time visualization of anatomical, functional, and molecular information in living tissues. This innovative imaging solution enhances the ability of healthcare professionals to detect tumors and inflammatory diseases non-invasively, thereby facilitating preclinical and clinical trials. By advancing its technology, iThera Medical aims to improve diagnostic capabilities and patient outcomes in the medical field.

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, established in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm specializes in developing advanced diagnostics for the early detection of various cancers, focusing on Stage I and Stage II malignancies where timely intervention can significantly improve patient outcomes. Utilizing a combination of infrared spectroscopy and artificial intelligence, Dxcover's technology enables the detection of cancer from a simple blood sample, allowing for same-day diagnosis and patient stratification. This innovative approach aims to enhance treatment options and ultimately improve survival rates and quality of life for patients.

Resistell AG is a Swiss company founded in 2018, based in Muttenz, specializing in the development and marketing of innovative diagnostic devices for antibiotic susceptibility testing. The company's platform employs advanced nanomotion technology to detect the movement of living bacterial cells, allowing for the rapid identification of bacterial resistance to antibiotics. This method serves as an alternative to traditional culture-based antibiograms, enabling healthcare providers to administer appropriate antibiotics in a timely manner, ultimately improving patient outcomes.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, founded in 2019. It specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. The company has created the world's first graphene-based brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation. This innovative technology allows for real-time monitoring and adaptive, personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. By utilizing AI-driven solutions, INBRAIN maximizes therapeutic outcomes while minimizing side effects. The company is also expanding its capabilities through strategic partnerships, including collaborations with Merck KGaA and its subsidiary INNERVIA Bioelectronics, to explore applications in peripheral nerve and systemic diseases, advancing the field of neurotechnology and bioelectronics.

Protinhi Therapeutics is a preclinical stage biotechnology company focused on the development of antiviral drugs aimed at combating various viral threats, including dengue, Zika, and COVID-19. The company utilizes proprietary technology and compounds to create therapies that inhibit viral proteases, effectively preventing the viruses from replicating. This mechanism allows healthcare providers to better control the spread of these diseases, addressing significant public health challenges.

Xenikos is a biopharmaceutical company focused on developing innovative immunotherapy treatments aimed at restoring health to patients suffering from serious immune diseases and transplant rejection. The company specializes in creating anti-T-cell antibodies that act as a therapeutic tool to reset the immune system. Once administered, these antibodies specifically target and eliminate activated adult T cells, allowing for improved treatment outcomes in various medical conditions. By harnessing the potential of antibody action, Xenikos aims to provide efficient solutions that can significantly enhance patient recovery and overall well-being.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, founded in 2019. It specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. The company has created the world's first graphene-based brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation. This innovative technology allows for real-time monitoring and adaptive, personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. By utilizing AI-driven solutions, INBRAIN maximizes therapeutic outcomes while minimizing side effects. The company is also expanding its capabilities through strategic partnerships, including collaborations with Merck KGaA and its subsidiary INNERVIA Bioelectronics, to explore applications in peripheral nerve and systemic diseases, advancing the field of neurotechnology and bioelectronics.

Herantis Pharma is a biotech company focused on addressing unmet clinical needs, particularly in the field of neurodegenerative diseases. The company's primary development program centers on HER-096, a peptidomimetic molecule designed to mimic the biological activity of the neuroprotective CDNF protein. By targeting Parkinson's disease, Herantis Pharma aims to develop disease-modifying therapies that could significantly improve patient outcomes.

Herantis Pharma is a biotech company focused on addressing unmet clinical needs, particularly in the field of neurodegenerative diseases. The company's primary development program centers on HER-096, a peptidomimetic molecule designed to mimic the biological activity of the neuroprotective CDNF protein. By targeting Parkinson's disease, Herantis Pharma aims to develop disease-modifying therapies that could significantly improve patient outcomes.

AkknaTek is a company specializing in the development of patented optical testing technology aimed at improving patient visual outcomes, particularly in the context of intraocular lenses (IOLs). Its flagship product is a lens reviewer designed to assist in the postoperative management of dislocated IOLs, making the treatment process more intuitive and accessible for clinics. By minimizing the risk of unexpected refractive complications following cataract surgery, AkknaTek's technology not only enhances the safety and effectiveness of IOL implants but also reduces the likelihood of the need for additional refractive procedures. The company's innovative approach contributes significantly to better postoperative care for patients undergoing cataract surgery.

VIVAN Therapeutics is a company focused on developing personalized cancer therapeutics aimed at revolutionizing cancer care. Utilizing a novel assay technology licensed from the Center for Personalized Cancer Therapeutics at Mt Sinai New York, VIVAN offers a comprehensive genomics-based drug screening service that integrates blockchain technology. The company's approach includes the Personal Discovery Process (PDP), which treats each patient as a unique case by engineering their tumor's genetic complexity into a model using fruit flies, allowing for the evaluation of both FDA-approved cancer and non-cancer drugs. This innovative strategy aims to provide less toxic and more affordable treatment options, enhancing the effectiveness of cancer care through tailored recommendations and the development of new diagnostics and decision support tools.

Vigor Medical Technologies Ltd. specializes in the development and commercialization of innovative medical devices aimed at treating chest trauma and facilitating thoracic and abdominal drainage. With over 4 million cases of chest trauma reported annually, which is a leading cause of accidental death, the company addresses a critical need in emergency medicine. Vigor's products include self-fixation sealing devices that effectively prevent lung and heart collapse, conditions that can be fatal if not promptly identified and managed. Additionally, the company's devices feature a hermetic seal and an open drainage shaft, allowing them to seal off wounds regardless of contamination from dirt, blood, or other materials. This technology is designed to support both military and civilian first aid organizations, as well as hospitals, enhancing the effectiveness of emergency care in critical situations.

Cherry Biotech is a biomedical technology company specializing in Organ on Chip systems that facilitate drug discovery and personalized medicine. The company focuses on developing microfluidic technology that allows for the culture and simulation of human organs under various physiological and pathological conditions. Cherry Biotech also provides temperature controllers for rapid temperature adjustments and next-generation 3D cell culture technologies. These innovations assist clinicians in accurately recapitulating the human cellular microenvironment, which is crucial for drug development and toxicity assessment.

Arthex Biotech S.L. is a biotechnology company founded in 2019 and based in Paterna, Spain. It specializes in the development of antisense RNA treatments specifically aimed at addressing genetic diseases and disorders where microRNAs play a significant role. As a spin-off from the University of Valencia, Arthex Biotech leverages a strong foundation in drug discovery and has a team comprising experts with extensive experience in neuromuscular diseases. The company focuses on creating innovative therapies for conditions with unmet medical needs, providing new treatment options for patients suffering from rare genetic diseases and other high-need medical issues. With guidance from esteemed scientific and clinical advisors, Arthex Biotech is committed to advancing its product development to improve patient outcomes.

Arthex Biotech S.L. is a biotechnology company founded in 2019 and based in Paterna, Spain. It specializes in the development of antisense RNA treatments specifically aimed at addressing genetic diseases and disorders where microRNAs play a significant role. As a spin-off from the University of Valencia, Arthex Biotech leverages a strong foundation in drug discovery and has a team comprising experts with extensive experience in neuromuscular diseases. The company focuses on creating innovative therapies for conditions with unmet medical needs, providing new treatment options for patients suffering from rare genetic diseases and other high-need medical issues. With guidance from esteemed scientific and clinical advisors, Arthex Biotech is committed to advancing its product development to improve patient outcomes.

ATXA Therapeutics Limited is a Dublin-based pharmaceutical company established in 2015 as a spin-out from University College Dublin. The company specializes in developing novel small molecule drugs aimed specifically at treating pulmonary arterial hypertension (PAH), addressing a significant unmet medical need. Founded by Professor Therese Kinsella, ATXA builds on more than 20 years of research, focusing on human prostanoid receptors and their implications in cardiovascular diseases and oncology. The company has received substantial grant funding and has developed a portfolio of highly selective small molecule drugs, validating their effectiveness for various conditions, notably PAH. ATXA's research strategy targets improvements in treatment efficacy by employing human thromboxane receptor antagonists, which enhance vasodilation and mitigate vasoconstriction. The team's expertise spans multiple disciplines, including cardiovascular biology, cancer biology, and drug discovery, positioning ATXA to advance the clinical development of therapies that significantly improve upon existing standards of care for patients with PAH.

ATXA Therapeutics Limited is a Dublin-based pharmaceutical company established in 2015 as a spin-out from University College Dublin. The company specializes in developing novel small molecule drugs aimed specifically at treating pulmonary arterial hypertension (PAH), addressing a significant unmet medical need. Founded by Professor Therese Kinsella, ATXA builds on more than 20 years of research, focusing on human prostanoid receptors and their implications in cardiovascular diseases and oncology. The company has received substantial grant funding and has developed a portfolio of highly selective small molecule drugs, validating their effectiveness for various conditions, notably PAH. ATXA's research strategy targets improvements in treatment efficacy by employing human thromboxane receptor antagonists, which enhance vasodilation and mitigate vasoconstriction. The team's expertise spans multiple disciplines, including cardiovascular biology, cancer biology, and drug discovery, positioning ATXA to advance the clinical development of therapies that significantly improve upon existing standards of care for patients with PAH.

Hemispherian is a biotechnology firm focused on developing innovative treatments for various types of cancer, particularly aggressive forms such as glioblastoma multiforme. The company specializes in creating personalized cancer therapies and is engaged in the development of a novel class of small-molecule drugs. By concentrating on areas of unmet medical need, Hemispherian aims to provide physicians with access to advanced therapeutic options that could improve patient outcomes in challenging cancer cases.

Hemispherian is a biotechnology firm focused on developing innovative treatments for various types of cancer, particularly aggressive forms such as glioblastoma multiforme. The company specializes in creating personalized cancer therapies and is engaged in the development of a novel class of small-molecule drugs. By concentrating on areas of unmet medical need, Hemispherian aims to provide physicians with access to advanced therapeutic options that could improve patient outcomes in challenging cancer cases.

Immunethep is a biotechnology company specializing in the development of immunotherapies for immune system-related diseases. Originating as a spin-off from the University of Porto, the company has leveraged its proprietary technology to uncover a novel mechanism by which various pathogenic bacteria inhibit the host immune response. This discovery enables Immunethep to create broad-spectrum anti-bacterial immunotherapies. Among its initiatives, the company is developing neonatal vaccines aimed at protecting infants from bacterial infections while still in the womb, allowing for the enhancement of immunity and prevention of multi-bacterial infections. Through its innovative approach, Immunethep addresses significant unmet medical needs in the realm of infectious diseases.

Immunethep is a biotechnology company specializing in the development of immunotherapies for immune system-related diseases. Originating as a spin-off from the University of Porto, the company has leveraged its proprietary technology to uncover a novel mechanism by which various pathogenic bacteria inhibit the host immune response. This discovery enables Immunethep to create broad-spectrum anti-bacterial immunotherapies. Among its initiatives, the company is developing neonatal vaccines aimed at protecting infants from bacterial infections while still in the womb, allowing for the enhancement of immunity and prevention of multi-bacterial infections. Through its innovative approach, Immunethep addresses significant unmet medical needs in the realm of infectious diseases.

Nanordica Medical is an Estonian medical technology company specializing in advanced wound care solutions. The company has developed a patented nanotechnology that combines copper and silver in nanofibers to effectively remove infections and promote healing in chronic wounds. Nanordica Medical has launched a veterinary product, Ravimus Vet, designed for treating animal wounds, while also focusing on a first-in-class wound dressing for challenging human conditions, such as diabetic foot ulcers. Recent clinical trials have demonstrated that their wound dressing outperforms traditional silver ion-based dressings across multiple efficacy parameters, offering a more powerful antibacterial effect that can inactivate a wider range of bacteria, including drug-resistant strains.

AkknaTek is a company specializing in the development of patented optical testing technology aimed at improving patient visual outcomes, particularly in the context of intraocular lenses (IOLs). Its flagship product is a lens reviewer designed to assist in the postoperative management of dislocated IOLs, making the treatment process more intuitive and accessible for clinics. By minimizing the risk of unexpected refractive complications following cataract surgery, AkknaTek's technology not only enhances the safety and effectiveness of IOL implants but also reduces the likelihood of the need for additional refractive procedures. The company's innovative approach contributes significantly to better postoperative care for patients undergoing cataract surgery.

Protinhi Therapeutics is a preclinical stage biotechnology company focused on the development of antiviral drugs aimed at combating various viral threats, including dengue, Zika, and COVID-19. The company utilizes proprietary technology and compounds to create therapies that inhibit viral proteases, effectively preventing the viruses from replicating. This mechanism allows healthcare providers to better control the spread of these diseases, addressing significant public health challenges.

Innitius specializes in developing diagnostic devices aimed at enhancing women's health, particularly in the context of preterm birth. Utilizing innovative torsional ultrasound technology, the company has created a patented intravaginal probe that transmits torsional waves to assess changes in tissue consistency. This technology enables medical practitioners to evaluate the risk of preterm birth and the likelihood of successful labor induction. By providing actionable diagnostics, Innitius helps healthcare providers accurately identify false indications of premature labor, thereby improving patient care and outcomes in obstetrics.

Kahun is a healthcare technology company that offers an online medical platform designed to assist physicians in making informed clinical decisions. By cataloging clinical information from peer-reviewed medical literature, Kahun's platform employs artificial intelligence diagnostic engines to extract relevant insights. This approach not only streamlines the clinical intake process but also enhances the transparency and explainability of healthcare decisions. By optimizing physicians' documentation time and overall cognitive load, Kahun aims to improve clinical outcomes and facilitate faster, evidence-based decision-making within healthcare organizations.

Restore Medical is a medical device company based in Or Yehuda, Israel, established in 2016. The company specializes in providing innovative treatment solutions for patients suffering from congestive heart failure. Its flagship product, ContraBand, is a catheter-delivered implant designed specifically for patients with left ventricle failure who have preserved right ventricle function. This device aims to enhance left ventricle ejection fraction, minimize mitral regurgitation, and restore optimal ventricular geometry. By addressing these critical issues, Restore Medical's technology seeks to significantly improve patient quality of life and decrease rates of hospital readmission.

Ovagen is a biotechnology company specializing in the production of germ-free (GF) chicken eggs and GF birds in commercial quantities, primarily for the pharmaceutical industry. The company has developed a unique process that enables large-scale production of recombinant proteins to Good Manufacturing Practice (GMP) standards using a transgenic chicken platform. This innovative approach provides pharmaceutical companies with a biosecure, flexible, and cost-effective biomanufacturing solution for vaccines and therapeutic proteins. In addition to its core production capabilities, Ovagen offers Contract Research Services and possesses extensive expertise in specific poultry and rodent research technologies, as well as in the housing and husbandry of specific pathogen-free (SPF) poultry and rodents.

Antabio is a private biopharmaceutical company based in Labege, France, focused on developing innovative treatments for drug-resistant infections, particularly targeting critical priority pathogens. Founded in 2009, the company specializes in creating novel antibacterial resistance-breakers, including stand-alone inhibitors of bacterial metalloenzymes. These inhibitors are designed to be combined with existing antibiotics, such as carbapenems, to restore their efficacy against the most challenging pathogens responsible for life-threatening infections, including carbapenem-resistant nosocomial pneumonia. Antabio aims to address significant unmet medical needs in the treatment of drug-resistant infections, ultimately providing healthcare professionals with effective medicinal products to combat these critical health challenges. The company has been recognized for its work, receiving a Wellcome Trust Seeding Drug Discovery Award.

Antabio is a private biopharmaceutical company based in Labege, France, focused on developing innovative treatments for drug-resistant infections, particularly targeting critical priority pathogens. Founded in 2009, the company specializes in creating novel antibacterial resistance-breakers, including stand-alone inhibitors of bacterial metalloenzymes. These inhibitors are designed to be combined with existing antibiotics, such as carbapenems, to restore their efficacy against the most challenging pathogens responsible for life-threatening infections, including carbapenem-resistant nosocomial pneumonia. Antabio aims to address significant unmet medical needs in the treatment of drug-resistant infections, ultimately providing healthcare professionals with effective medicinal products to combat these critical health challenges. The company has been recognized for its work, receiving a Wellcome Trust Seeding Drug Discovery Award.

PhosPrint, established in 2019 and headquartered in Agia Paraskevi, Attiki, specializes in laser bioprinting systems and regenerative medicine. The company's core business involves developing and providing on-site cell printing during surgeries, aiming to facilitate tissue regeneration and advance medical research. PhosPrint's offerings include healthcare technology products that leverage laser bioprinting and biotechnology research, enabling researchers and medical professionals to access innovative tools and procedures to combat diseases and medical conditions.

Synergia Medical is focused on the development and commercialization of next-generation neurostimulation devices, leveraging optoelectronics technology. The company specializes in creating MRI-safe, implantable neurostimulators designed primarily for drug-resistant epilepsy, with potential applications in various therapeutic areas. By replacing traditional wires with fiber optics, Synergia's devices utilize photovoltaic cells to convert optical energy into electrical impulses, enhancing their functionality and safety. Over a brief period of three years, Synergia Medical has achieved ISO13485 certification, successfully developed and marketed an OEM external neurostimulator for motorized prosthetic arms, and launched its initial NAOS platform. Supported by private investors and public research grants, the company has expanded its team to thirteen highly skilled professionals with extensive experience in the field, underscoring its commitment to innovation in neurostimulation technology.

AuriGen Medical Limited is an innovative company based in Dublin, Ireland, specializing in electrophysiology and structural heart solutions. Founded in 2016, AuriGen develops advanced left atrial appendage (LAA) implants aimed at addressing the stroke and arrhythmia risks associated with persistent atrial fibrillation (AF). The company targets a significant and growing patient population, particularly those with medication-resistant AF, which affects over three million individuals across the United States and Europe. AuriGen's technology offers a novel trans-septal implant that not only treats AF effectively but also reduces the reliance on anticoagulants and anti-arrhythmic medications. By providing cost-effective treatment options, AuriGen aims to improve patient outcomes while addressing the rising financial burden of managing chronic cardiac conditions in aging populations.

Qubit Pharmaceuticals is a Paris-based company established in 2020, focusing on innovative technology for pharmaceutical drug discovery. Founded by prominent academic institutions and researchers, including CNAM, CNRS, the University of Texas at Austin, Sorbonne University, and Washington University, the company leverages over 20 years of research and development. Qubit Pharmaceuticals has developed a drug discovery simulation platform that aims to significantly reduce the cost and duration of preclinical drug development. Utilizing proprietary force field models and molecular dynamics calculations, the platform facilitates virtual screening and visualization of potential drug candidates. By integrating principles of quantum physics, Qubit Pharmaceuticals supports biopharmaceutical companies in accelerating their research and development processes, ultimately enhancing the efficiency of drug discovery.

Elicera Therapeutics is a clinical-stage immuno-oncology company based in Sweden that focuses on developing innovative cell and gene therapies to treat cancer. The company’s portfolio includes four drug candidates: two oncolytic virus therapies, ELC-100 and ELC-201, and two CAR T-cell treatments, ELC-301 and ELC-401. Additionally, Elicera has developed a universal CAR T-cell technology platform named iTANK (ELC-001), designed to enhance the efficacy of CAR T-cell therapies by enabling a multi-targeted approach against solid tumors. With its commitment to advancing immune-based cancer treatments, Elicera Therapeutics aims to improve outcomes for patients facing various forms of cancer.

Neurosoft Bioelectronics is a Swiss company specializing in the development of soft implantable electrodes designed for interfacing with the nervous system. The company focuses on creating advanced neural implants that can record and stimulate the brain, spinal cord, and peripheral nerves, addressing the limitations of traditional stiff devices that hinder patient outcomes. Its flagship product, the SOFT ECoG, is a subdural electrode that facilitates effective brain monitoring and stimulation while minimizing electrical resistance and MRI artifacts. This innovative technology aims to achieve long-term bio-integration with neural tissues, adapting to both static and dynamic mechanical properties, which enhances therapeutic capabilities for patients suffering from neurological disorders. Ultimately, Neurosoft Bioelectronics strives to improve clinical outcomes and expand the potential applications of neural interfaces in healthcare.

Legacy Healthcare is a biotechnology company dedicated to developing safer drug solutions for the treatment of autoimmune and inflammatory diseases, particularly focusing on fragile patient populations such as children, cancer patients, and the elderly. The company specializes in addressing the challenges of moderate to severe alopecia areata, an autoimmune condition that causes significant hair loss and may lead to lifelong relapses. By creating innovative treatments that are safe for patients who may already be on multiple medications, Legacy Healthcare aims to enhance the quality of life for individuals affected by this condition and other chronic diseases.

Nuclidium is a developer of innovative radiopharmaceutical tracers aimed at enhancing the detection and staging of cancer. The company's platform focuses on creating novel diagnostic and therapeutic tracers that target specific molecules present in tumors. By accurately identifying these targets, Nuclidium enables personalized treatment options that share similar chemical properties and biological molecular targets. This approach aims to significantly improve treatment outcomes and long-term survival for cancer patients while addressing the unmet needs in cancer diagnostics.

Piomic Medical is a developer of a non-invasive medical device aimed at treating chronic wounds, particularly leg and foot ulcers. The company has created the COMS® One Therapy System, a portable, hand-held device that utilizes optical and magnetic stimulation technologies to promote wound healing. This device is designed to be user-friendly, featuring a single button operation, and can be utilized in both clinical settings and patients' homes. Clinical studies have demonstrated that the COMS® system is safe and effective, resulting in accelerated wound closure, reduced pain, and improved quality of life for patients. By providing a lightweight and efficient solution, Piomic Medical addresses the significant challenge posed by hard-to-heal wounds, which affect millions of individuals and impose a considerable burden on healthcare systems worldwide.

Ovagen is a biotechnology company specializing in the production of germ-free (GF) chicken eggs and GF birds in commercial quantities, primarily for the pharmaceutical industry. The company has developed a unique process that enables large-scale production of recombinant proteins to Good Manufacturing Practice (GMP) standards using a transgenic chicken platform. This innovative approach provides pharmaceutical companies with a biosecure, flexible, and cost-effective biomanufacturing solution for vaccines and therapeutic proteins. In addition to its core production capabilities, Ovagen offers Contract Research Services and possesses extensive expertise in specific poultry and rodent research technologies, as well as in the housing and husbandry of specific pathogen-free (SPF) poultry and rodents.

TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses to enhance T-cell therapies for cancer treatment. Established in 2013, the company focuses on utilizing its patented technology to improve tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibiting antibody treatments. TILT Biotherapeutics is advancing products such as TILT-123, TILT-234, and TILT-321, which aim to modify the tumor microenvironment and boost immune responses against cancer. The company's innovative approach holds promise for achieving effective results in treating solid tumors, paralleling the successes seen in hematological tumors.

Genetika+ is a medical platform focused on personalizing treatment for depression by utilizing advanced biological, medical, and genetic data. The company has developed an innovative testing tool that predicts the most effective drug therapy for individual patients, thus enabling faster treatment solutions with reduced side effects and lower dosing requirements. By employing a combination of stem-cell technology, genomics, and artificial intelligence, Genetika+ aims to optimize treatment while also aiding pharmaceutical companies in enhancing their product offerings and streamlining clinical trials. This approach not only tailors treatments to specific patient needs but also seeks to advance care for psychiatric and neurological conditions.

BrainEver is a medical research company focused on developing innovative drugs for neurodegenerative disorders. Building on research by Alain Prochiantz and his team, BrainEver investigates the role of homeoproteins, which are essential for brain development and ongoing neuronal functions. The company hypothesizes that administering homeoproteins can enhance the physiological resilience of neurons and improve clinical symptoms in patients. Among its drug candidates, Engrailed 1 (BREN01) is the most advanced, aimed at treating Parkinson Disease and Amyotrophic Lateral Sclerosis (ALS). Additionally, BrainEver is actively developing a pipeline of four more drug candidates targeting other neurodegenerative conditions, including Huntington Disease and Optic Neuropathies. Through its research and development efforts, BrainEver seeks to provide effective therapeutic options for healthcare practitioners and their patients.

InVera Medical is focused on developing innovative medical devices aimed at treating varicose veins and venous ulcers. The company is creating BioVena™, a less invasive and pain-free treatment option that utilizes the body's natural biological response to address venous diseases. This proprietary technology positions InVera Medical to significantly improve patient outcomes by providing a safer and more effective alternative to existing treatment methods. With only a small fraction of the 120 million individuals suffering from venous disease receiving adequate endovenous treatment annually, InVera Medical seeks to broaden access to effective care for a population largely underserved by current solutions. The company’s advancements are particularly crucial given the high annual costs associated with venous ulcers, which amount to approximately $33 billion for insurers in the US and EU. By targeting the full spectrum of venous disease, InVera Medical aims to enhance the quality of life for patients who have long been limited to ineffective compression bandaging.

Betalin Therapeutics is a privately-held company dedicated to developing innovative cell therapy solutions for insulin-dependent diabetes through its Engineered Micro-Pancreas (EMP) technology. This platform combines harvested pancreatic islets, known as Islets of Langerhans, with a proprietary biological micro-environment designed to support these cells. The EMP aims to offer an alternative to traditional insulin therapy, potentially eliminating the need for insulin injections and glucose monitoring in patients. Following promising in-vitro and preliminary in-vivo results, Betalin Therapeutics is focused on optimizing the therapy using animal models and preparing to submit an Investigational New Drug (IND) application to the FDA in anticipation of advancing to clinical trials.

Yonalink operates a global network comprising over 30,000 medical centers. It specializes in real-time collection of clinical trial data through its platform, which streamlines electronic health records (EHR) to electronic data capture (EDC), employs AI-driven case report form (CRF) data mapping, and facilitates secure, automated migration of research data from health records. This service enhances trial efficiency, improves data quality, reduces staff burnout at medical centers, and expands access to novel patient care opportunities. Additionally, the platform enables management of clinical trial operations and vendors, accelerates drug and device development, promotes patient diversity and enrollment, and ensures secure, fast, and error-free data capture processes for healthcare providers and researchers.

Xeltis AG, established in 2006, is a clinical-stage medical device company based in Zurich, Switzerland, with additional operations in the Netherlands and the USA. The company specializes in developing bio-absorbable heart valves and blood vessels using a proprietary polymer-based technology. Xeltis' RestoreX platform enables the body's natural healing system to develop tissue that replaces the implant, forming a new functional valve or vessel. The company's restorative devices include implantable small diameter blood vessels for hemodialysis and coronary artery bypass graft (CABG) surgery, as well as pulmonary heart valves, with ongoing clinical trials. Xeltis has raised funding from various venture capital firms and European institutions, including a €30 million round in 2021.

Xeltis AG, established in 2006, is a clinical-stage medical device company based in Zurich, Switzerland, with additional operations in the Netherlands and the USA. The company specializes in developing bio-absorbable heart valves and blood vessels using a proprietary polymer-based technology. Xeltis' RestoreX platform enables the body's natural healing system to develop tissue that replaces the implant, forming a new functional valve or vessel. The company's restorative devices include implantable small diameter blood vessels for hemodialysis and coronary artery bypass graft (CABG) surgery, as well as pulmonary heart valves, with ongoing clinical trials. Xeltis has raised funding from various venture capital firms and European institutions, including a €30 million round in 2021.

Filterlex Medical Ltd., established in 2015 and based in Yokneam, Israel, specializes in developing innovative embolic protection devices for the cardiovascular field. The company's flagship product, CAPTIS, is a full-body embolic protection device designed to reduce the risk of stroke and other complications during catheter-based structural heart procedures. Filterlex aims to address the limitations of current products by offering a device that can be intuitively deployed and retrieved, providing comprehensive protection by deflecting, capturing, and removing embolic particles. The company is currently seeking seed funding to support its growth and product development efforts.

VBL Therapeutics is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel treatments for cancer and immune-inflammatory diseases. The company utilizes two proprietary platform technologies that harness the body's natural physiological and genetic regulatory elements. Its lead product candidate, VB-111, is a gene-based biologic aimed at treating solid tumors, specifically recurrent glioblastoma, an aggressive form of brain cancer. In addition to its oncology efforts, VBL Therapeutics is pursuing programs that target anti-inflammatory diseases, leveraging its Lecinoxoid platform technology. The company's diverse portfolio reflects its commitment to advancing innovative therapeutic solutions in the biopharmaceutical landscape.

VBL Therapeutics is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel treatments for cancer and immune-inflammatory diseases. The company utilizes two proprietary platform technologies that harness the body's natural physiological and genetic regulatory elements. Its lead product candidate, VB-111, is a gene-based biologic aimed at treating solid tumors, specifically recurrent glioblastoma, an aggressive form of brain cancer. In addition to its oncology efforts, VBL Therapeutics is pursuing programs that target anti-inflammatory diseases, leveraging its Lecinoxoid platform technology. The company's diverse portfolio reflects its commitment to advancing innovative therapeutic solutions in the biopharmaceutical landscape.

Criam is a biotechnology company based in Braga, Portugal, founded in 2015. It specializes in the research and development of a medical device that facilitates blood type analysis and the detection of various infectious diseases, including HIV, Brucella, tick fever, syphilis, mononucleosis, and meningitis. The company's portable platform operates independently of electricity and does not require additional laboratory infrastructure, making it accessible for use in diverse settings. Criam's device allows for rapid and accurate blood testing, which enhances clinical decision-making by providing timely health information. The technology is designed to be scalable, with one reader capable of performing multiple tests using specialized cartridges and computer vision algorithms. This innovation aims to improve the efficiency and reliability of blood testing services, ultimately enhancing patient care.

Innoventric is a medical device company based in Ness-Ziona, Israel, focused on developing innovative percutaneous solutions for Tricuspid Regurgitation and right heart disease. Founded in 2017, the company has made significant advancements with its proprietary Trillium™ technology, designed to treat Tricuspid Valve Regurgitation. Innoventric's device features a functional tricuspid valve replacement that employs cross-caval anchoring and a multi-valve design, aimed at enhancing blood flow regulation. The company has conducted over ten implantations of the Trillium™ technology as part of its first human clinical trial in Europe. Additionally, Innoventric maintains a comprehensive patent portfolio for the Trillium™ and related technologies, positioning itself as a key player in the structural heart medical device sector.

Healium Medical Ltd is a medical technology company based in Yokneam Illit, Israel, founded in 2017. The company specializes in the development of a non-contact guided ultrasound ablation system aimed at treating atrial fibrillation. Its innovative technology features a miniature ultrasound transducer that enables contactless circumferential pulmonary vein isolation, offering real-time lesion monitoring capabilities. This system simplifies the procedural workflow, reduces procedure time, and enhances efficacy compared to traditional methods that require direct tissue contact and extensive catheter maneuvering. Healium Medical's solutions represent a significant advancement in the treatment of atrial fibrillation, aiming to improve patient outcomes and procedural efficiency.

Healium Medical Ltd is a medical technology company based in Yokneam Illit, Israel, founded in 2017. The company specializes in the development of a non-contact guided ultrasound ablation system aimed at treating atrial fibrillation. Its innovative technology features a miniature ultrasound transducer that enables contactless circumferential pulmonary vein isolation, offering real-time lesion monitoring capabilities. This system simplifies the procedural workflow, reduces procedure time, and enhances efficacy compared to traditional methods that require direct tissue contact and extensive catheter maneuvering. Healium Medical's solutions represent a significant advancement in the treatment of atrial fibrillation, aiming to improve patient outcomes and procedural efficiency.

iThera Medical is a biotechnology company founded in 2010 as a spin-off from the Helmholtz Zentrum Muenchen, specializing in photonic molecular imaging technology. The company focuses on the development of its proprietary multispectral optoacoustic tomography (MSOT) technology, which offers real-time visualization of anatomical, functional, and molecular information in living tissues. This innovative imaging solution enhances the ability of healthcare professionals to detect tumors and inflammatory diseases non-invasively, thereby facilitating preclinical and clinical trials. By advancing its technology, iThera Medical aims to improve diagnostic capabilities and patient outcomes in the medical field.

InProTher Aps is a biotechnology company based in Copenhagen, Denmark, focusing on the development of innovative vaccine technologies and candidates within the field of immunotherapy. Established in 2011, the company is dedicated to creating the first adaptive immune therapy that targets immunosuppressive genes associated with ancient retroviruses. InProTher is also engaged in the development of products aimed at combating HIV, papilloma viruses, and various forms of cancer. Through its research and development efforts, InProTher seeks to advance treatment options in the evolving landscape of immunotherapy.

iThera Medical is a biotechnology company founded in 2010 as a spin-off from the Helmholtz Zentrum Muenchen, specializing in photonic molecular imaging technology. The company focuses on the development of its proprietary multispectral optoacoustic tomography (MSOT) technology, which offers real-time visualization of anatomical, functional, and molecular information in living tissues. This innovative imaging solution enhances the ability of healthcare professionals to detect tumors and inflammatory diseases non-invasively, thereby facilitating preclinical and clinical trials. By advancing its technology, iThera Medical aims to improve diagnostic capabilities and patient outcomes in the medical field.

Epigene Labs SAS is a biotechnology firm focused on enhancing precision oncology through its advanced technology platform that utilizes artificial intelligence. Founded in 2019 and headquartered in Paris, France, with an additional office in Boston, Massachusetts, the company addresses the significant challenges of aggregating, analyzing, and visualizing extensive genomic data in cancer research. By integrating proprietary data from partners with publicly available datasets, Epigene Labs provides medical researchers with actionable insights and user-friendly analytics. The company collaborates with leading cancer centers and prominent biotech firms to develop intelligence-augmenting services that support drug discovery and research in precision oncology. Its innovative approach aims to transform genomic data into effective strategies for targeted cancer therapies.

NETRIS Pharma S.A.S. is a biotechnology company based in Lyon, France, focused on the identification and development of therapeutic molecules aimed at treating various forms of cancer. Established in 2008, the company specializes in targeting dependence receptors, which are trans-membrane proteins that play a crucial role in cellular signaling and tumor control. NETRIS Pharma conducts both in vitro and in vivo research, as well as preclinical practices, to manufacture drugs specifically for the treatment of breast cancer, lung cancer, glioblastoma, and neuroblastoma. Through its innovative approach, the company aims to advance cancer therapies and contribute to improved patient outcomes in the pharmaceutical industry.

Amadix is a biotechnology company focused on the development and commercialization of innovative cancer diagnostic technologies that address unmet medical needs in oncology. The company aims to enhance early cancer detection through non-invasive methods, significantly improving patient outcomes and reducing the complications associated with traditional invasive procedures like tumor biopsies. Amadix's flagship product, Colofast, is a non-invasive blood test designed for the screening of colorectal cancer and advanced adenoma diagnosis, targeting the high mortality rate associated with this disease. The company is committed to validating its products through international multicenter studies to ensure clinical efficacy before global commercialization. The team at Amadix comprises experienced professionals with extensive backgrounds in oncology diagnostics, the pharmaceutical industry, and biotechnology, supported by an independent board of advisors with deep expertise in oncology and diagnostics, guiding the company's strategic and commercial efforts.

NETRIS Pharma S.A.S. is a biotechnology company based in Lyon, France, focused on the identification and development of therapeutic molecules aimed at treating various forms of cancer. Established in 2008, the company specializes in targeting dependence receptors, which are trans-membrane proteins that play a crucial role in cellular signaling and tumor control. NETRIS Pharma conducts both in vitro and in vivo research, as well as preclinical practices, to manufacture drugs specifically for the treatment of breast cancer, lung cancer, glioblastoma, and neuroblastoma. Through its innovative approach, the company aims to advance cancer therapies and contribute to improved patient outcomes in the pharmaceutical industry.

Yonalink operates a global network comprising over 30,000 medical centers. It specializes in real-time collection of clinical trial data through its platform, which streamlines electronic health records (EHR) to electronic data capture (EDC), employs AI-driven case report form (CRF) data mapping, and facilitates secure, automated migration of research data from health records. This service enhances trial efficiency, improves data quality, reduces staff burnout at medical centers, and expands access to novel patient care opportunities. Additionally, the platform enables management of clinical trial operations and vendors, accelerates drug and device development, promotes patient diversity and enrollment, and ensures secure, fast, and error-free data capture processes for healthcare providers and researchers.

EpiEndo Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on treating inflammatory disorders by enhancing epithelial barrier integrity, a crucial factor in various diseases. Epithelial cells comprise significant components of human skin, lung tissue, the intestinal tract, and genitalia, with compromised barrier integrity linked to persistent inflammation. EpiEndo is developing a proprietary portfolio of orally available macrolide drug candidates aimed at addressing the substantial global burden of chronic respiratory diseases and other unmet medical needs. Its lead candidate, EP395, is designed to be the first oral, disease-modifying, non-antibiotic macrolide that strengthens barriers and reduces inflammation, targeting conditions such as chronic obstructive pulmonary disease (COPD) and other inflammatory airway diseases. Through its innovative approach, EpiEndo seeks to provide effective treatments that improve patient outcomes.

RemedyBio is an immunology-focused discovery and development company located in Dublin, Ireland. The company specializes in creating therapeutics aimed at enhancing immunotherapies for complex and heterogeneous diseases. RemedyBio has pioneered innovative techniques for understanding the immune system, particularly through its advanced discovery technology that accelerates the speed and scale of single-cell analysis. This technology supports next-generation applications in areas such as immuno-oncology, autoimmune diseases, and infectious diseases, ultimately offering the healthcare industry effective therapeutic and diagnostic solutions.

Vivasure Medical Limited is a medical device company based in Galway, Ireland, that specializes in the research, development, and manufacture of arterial and venous closure devices utilizing its patented PerQseal technology. The company focuses on creating polymer implants and delivery systems aimed at minimally invasive vessel closures, primarily in cardiology, interventional radiology, and vascular surgery. Its flagship product is an absorbable patch-based large-bore percutaneous closure device, designed to effectively close large arteriotomies resulting from transcatheter procedures, including transcatheter aortic valve replacement and endovascular aneurysm repair. Founded in 2008, Vivasure Medical is committed to advancing techniques that enhance patient outcomes in vascular access procedures.

PROSION is a biotechnology company focused on developing innovative drug therapies for challenging medical conditions, particularly cancer and other hard-to-treat diseases such as diabetes, Alzheimer's, and cardiovascular diseases. Utilizing a proprietary platform, PROSION aims to target proline-rich motif binding domains, which are often considered undruggable. By leveraging unique chemical building blocks, the company seeks to unlock these difficult pharmaceutical targets, addressing significant unmet medical needs. Through its research and development efforts, PROSION strives to enhance treatment options and improve the survival and quality of life for patients facing these serious health challenges.

RUBYnanomed provides non-invasive monitoring of cancer progression. They enable the analysis of their phenotypic, genetic, and functional characteristics, facilitating unprecedentedly frequent monitoring of cancer progression in a minimally invasive, cost-efficient way. They enable oncologists to detect and analyze the evolution of cancer subtypes and therapeutic resistance mechanisms in each patient, providing personalized therapy insights to treat their patients.

Qubit Pharmaceuticals is a Paris-based company established in 2020, focusing on innovative technology for pharmaceutical drug discovery. Founded by prominent academic institutions and researchers, including CNAM, CNRS, the University of Texas at Austin, Sorbonne University, and Washington University, the company leverages over 20 years of research and development. Qubit Pharmaceuticals has developed a drug discovery simulation platform that aims to significantly reduce the cost and duration of preclinical drug development. Utilizing proprietary force field models and molecular dynamics calculations, the platform facilitates virtual screening and visualization of potential drug candidates. By integrating principles of quantum physics, Qubit Pharmaceuticals supports biopharmaceutical companies in accelerating their research and development processes, ultimately enhancing the efficiency of drug discovery.

Glycanostics is a start-up focused on developing innovative cancer diagnostic tests, specifically targeting prostate cancer. The company specializes in creating clinically validated and registered non-invasive liquid biopsy tests that analyze glycan changes on proteins, such as prostate-specific antigen (PSA). This technology aims to deliver accurate and affordable diagnostic solutions, assisting healthcare professionals in making informed decisions regarding the necessity of biopsies and monitoring patients post-biopsy. Through its advancements in cancer diagnostics, Glycanostics seeks to improve early detection and patient outcomes.